Eton Pharmaceuticals (ETON) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eton Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ETON shares.
View ETON analyst ratings or view top-rated stocks.

1 brokerages have issued 12-month price targets for Eton Pharmaceuticals' stock. Their ETON share price forecasts range from $10.00 to $10.00. On average, they expect the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 152.5% from the stock's current price.
View analysts price targets for ETON or view top-rated stocks among Wall Street analysts.

Eton Pharmaceuticals' stock was trading at $2.82 at the beginning of the year. Since then, ETON stock has increased by 40.4% and is now trading at $3.96.
View the best growth stocks for 2023 here.

Eton Pharmaceuticals saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 530,400 shares, a decline of 9.7% from the April 30th total of 587,500 shares. Based on an average trading volume of 47,900 shares, the short-interest ratio is presently 11.1 days. Approximately 2.4% of the company's shares are sold short.
View Eton Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ETON earnings forecast.

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) released its quarterly earnings results on Thursday, March, 16th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.03. The business earned $8.50 million during the quarter, compared to analyst estimates of $9.10 million. Eton Pharmaceuticals had a negative net margin of 26.05% and a negative trailing twelve-month return on equity of 52.12%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eton Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Myovant Sciences (MYOV), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC) and Moderna (MRNA).

(ETON) raised $22 million in an IPO on Wednesday, November 14th 2018. The company issued 3,600,000 shares at $6.00 per share. National Securities Corporation acted as the underwriter for the IPO.

Eton Pharmaceuticals trades on the NASDAQ under the ticker symbol "ETON."

Eton Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Westside Investment Management Inc. (2.03%), Acuitas Investments LLC (1.84%), Stratos Wealth Partners LTD. (0.36%), Lido Advisors LLC (0.17%), Blair William & Co. IL (0.14%) and Renaissance Technologies LLC (0.05%). Insiders that own company stock include Harrow Health, Inc, Opaleye Management Inc, Pharmaceutical Co Ltd Takeda and Sean Brynjelsen.
View institutional ownership trends.

Shares of ETON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ETON stock can currently be purchased for approximately $3.96.

Eton Pharmaceuticals (NASDAQ:ETON) has a market capitalization of $101.00 million and generates $24.38 million in revenue each year. The company earns $-9,020,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis.

Eton Pharmaceuticals' mailing address is 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010. The official website for the company is www.etonpharma.com. The company can be reached via phone at (847) 787-7361 or via email at investorrelations@etonpharma.com.